Beyond traditional treatments: vagal nerve stimulation for painful temporomandibular disorders.

IF 2.5 Q2 CLINICAL NEUROLOGY
Frontiers in pain research (Lausanne, Switzerland) Pub Date : 2026-07-23 eCollection Date: 2026-01-01 DOI:10.3389/fpain.2026.1860767
Rania Nuwailati, David P Darrow, Donald R Nixdorf
{"title":"Beyond traditional treatments: vagal nerve stimulation for painful temporomandibular disorders.","authors":"Rania Nuwailati, David P Darrow, Donald R Nixdorf","doi":"10.3389/fpain.2026.1860767","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Chronic temporomandibular disorders (TMD) can progress to refractory chronic pain in a subset of patients, for whom standard multimodal treatments often provide limited relief. Emerging neuromodulation therapies-particularly non-invasive vagal nerve stimulation (nVNS)-suggest a potential non-pharmacologic adjunct within multimodal strategies for managing persistent symptoms. This case series explores the use of non-invasive nVNS in conjunction with a multimodal treatment strategy for managing refractory pain in patients with chronic TMD.</p><p><strong>Methods: </strong>A retrospective review at the University of Minnesota TMD, Orofacial Pain and Dental Sleep Medicine Clinic, evaluated patients with chronic TMD pain treated with a multimodal treatment plan which included GammaCore nVNS device, by comparing their baseline data to outcomes at their most recent follow-up.</p><p><strong>Results: </strong>Three patients (mean age 44.3 ± 23.3 years) with refractory TMD pain were identified as having received nVNS therapy using the GammaCore device. Treatment duration ranged from 4.6 to 18.2 months and was self-administered three to four times per day. All three patients reported improvements in pain intensity, pain-related disability, and psychosocial functioning, in the context of a multimodal treatment plan that included nVNS.</p><p><strong>Discussion: </strong>Our limited clinical experience observed improvements across multiple domains relevant to patients with chronic TMD in the context of a multimodal treatment plan that included nVNS.IRB approval status: Approved STUDY00024420.</p>","PeriodicalId":73097,"journal":{"name":"Frontiers in pain research (Lausanne, Switzerland)","volume":"7 ","pages":"1860767"},"PeriodicalIF":2.5000,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13443317/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in pain research (Lausanne, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fpain.2026.1860767","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Chronic temporomandibular disorders (TMD) can progress to refractory chronic pain in a subset of patients, for whom standard multimodal treatments often provide limited relief. Emerging neuromodulation therapies-particularly non-invasive vagal nerve stimulation (nVNS)-suggest a potential non-pharmacologic adjunct within multimodal strategies for managing persistent symptoms. This case series explores the use of non-invasive nVNS in conjunction with a multimodal treatment strategy for managing refractory pain in patients with chronic TMD.

Methods: A retrospective review at the University of Minnesota TMD, Orofacial Pain and Dental Sleep Medicine Clinic, evaluated patients with chronic TMD pain treated with a multimodal treatment plan which included GammaCore nVNS device, by comparing their baseline data to outcomes at their most recent follow-up.

Results: Three patients (mean age 44.3 ± 23.3 years) with refractory TMD pain were identified as having received nVNS therapy using the GammaCore device. Treatment duration ranged from 4.6 to 18.2 months and was self-administered three to four times per day. All three patients reported improvements in pain intensity, pain-related disability, and psychosocial functioning, in the context of a multimodal treatment plan that included nVNS.

Discussion: Our limited clinical experience observed improvements across multiple domains relevant to patients with chronic TMD in the context of a multimodal treatment plan that included nVNS.IRB approval status: Approved STUDY00024420.

超越传统治疗:迷走神经刺激疼痛的颞下颌紊乱。
慢性颞下颌疾病(TMD)可发展为难治性慢性疼痛患者的一部分,对他们标准的多模式治疗往往提供有限的缓解。新兴的神经调节疗法,特别是无创迷走神经刺激(nVNS),提示了一种潜在的非药物辅助疗法,可用于治疗持续性症状的多模式策略。本病例系列探讨了非侵入性nVNS结合多模式治疗策略对慢性TMD患者难治性疼痛的治疗。方法:在明尼苏达大学TMD口腔面部疼痛和牙科睡眠医学诊所进行回顾性研究,通过比较他们的基线数据和最近随访的结果,评估使用包括GammaCore nVNS设备在内的多模式治疗方案治疗慢性TMD疼痛的患者。结果:3例难治性TMD疼痛患者(平均年龄44.3±23.3岁)采用GammaCore装置接受nVNS治疗。治疗持续时间从4.6到18.2个月不等,每天自我给药3到4次。在包括nVNS在内的多模式治疗方案的背景下,所有三名患者都报告了疼痛强度、疼痛相关残疾和社会心理功能的改善。讨论:我们有限的临床经验观察到,在包括nVNS在内的多模式治疗方案的背景下,与慢性TMD患者相关的多个领域都有改善。IRB批准状态:已批准STUDY00024420。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.10
自引率
0.00%
发文量
0
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书